The Vascular Endothelial Growth Factor (VEGF): A model of gene regulation and a marker of tumour aggressiveness. An obvious therapeutic target?;Le Vascular Endothelial Growth Factor (VEGF): un modèle de régulation d'expression génique et un marqueur d'agressivité tumorale. Une cible th́erapeutique évidente?

Journal de la Societe de Biologie

Volumn 203, Issue 2, 2009, Pages 181-192

  Grépin, Renaud ^a   Pagès, Gilles ^a  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

Angiogenesis; ERK signalisation pathway; Targeted therapy; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; ISOPROTEIN; MESSENGER RNA; MONOCLONAL ANTIBODY; ONCOPROTEIN; PROTEIN TYROSINE KINASE; RNA; SIGNAL PEPTIDE; TUMOR PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

3' UNTRANSLATED REGION; BIOSYNTHESIS; CANCER INVASION; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY; PROMOTER REGION; REVIEW; SIGNAL TRANSDUCTION; VASCULARIZATION;

3' UNTRANSLATED REGIONS; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENE PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN ISOFORMS; PROTEIN-TYROSINE KINASES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RNA, MESSENGER; RNA, NEOPLASM; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77952295454     PISSN: 12950661     EISSN: None     Source Type: Journal    
DOI: 10.1051/jbio/2009022     Document Type: Article

References (78)

1. Abdelrahim M., Baker C.H., Abbruzzese J.L., Safe S., Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst, 2006, 98, 855-868.
2. Abdelrahim M., Smith R. 3rd, Burghardt R., Safe S., Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res, 2004, 64, 6740-6749.
3. Abdulrauf S.I., Edvardsen K., Ho K.L., Yang X.Y., Rock J.P., Rosenblum M.L., Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J Neurosurg, 1998, 88, 513-520.
4. Aguayo A., Kantarjian H., Manshouri T., Gidel C., Estey E., Thomas D., Koller C., Estrov Z., O'Brien S., Keating M., Freireich E., Albitar M., Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood, 2000, 96, 2240-2245.
5. Bates D.O., Cui T.G., Doughty J.M., Winkler M., Sugiono M., Shields J.D., Peat D., Gillatt D., Harper S.J., VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res, 2002, 62, 4123-4131.
6. Bergers G., Benjamin L.E., Tumorigenesis and the angiogenic switch. Nat Rev Cancer, 2003, 3, 401-410.
7. Berra E., Benizri E., Ginouves A., Volmat V., Roux D., Pouysśegur J., HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. Embo J, 2003, 22, 4082-4090.
8. Borgstrom P., Gold D.P., Hillan K.J., Ferrara N., Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res, 1999, 19, 4203-4214.
9. Cao H., Deterding L.J., Venable J.D., Kennington E.A., Yates J.R., 3rd, Tomer K.B., Blackshear P.J., Identification of the anti-inflammatory protein tristetraprolin as a hyperphosphorylated protein by mass spectrometry and site-directed mutagenesis. Biochem J, 2006, 394, 285-297.
10. Ciais D., Cherradi N., Bailly S., Grenier E., Berra E., Pouysśegur J., Lamarre J., Feige J.J., Destabilization of vascular endothelial growth factor mRNA by the zinc-finger protein TIS11b. Oncogene, 2004, 23, 8673-8680.
11. Denduluri N., Yang S.X., Berman A.W., Nguyen D., Liewehr D.J., Steinberg S.M., Swain S.M., Circulating biomarkers of bevacizumab activity in patients with breast cancer. Cancer Biol Ther, 2008, 7, 15-20.
12. Doller A., Akool el S., Huwiler A., Muller R., Radeke H.H., Pfeilschifter J., Eberhardt W., Posttranslational modification of the AU-rich element binding protein HuR by protein kinase C delta elicits angiotensin II-induced stabilization and nuclear export of cyclooxygenase 2 mRNA.Mol Cell Biol, 2008, 28, 2608-2625.
13. Doller A., Huwiler A., Muller R., Radeke H.H., Pfeilschifter J., Eberhardt W., Protein kinase C alphadependent phosphorylation of the mRNA-stabilizing factor HuR: implications for posttranscriptional regulation of cyclooxygenase-2. Mol Biol Cell, 2007, 18, 2137-2148.
14. Dvorak H.F., Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol, 2002, 20, 4368-4380.
15. Dvorak H.F., Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med, 1986, 315, 1650-1659.
16. Ellis L.M., Hicklin D.J., VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer, 2008, 8, 579-591.
17. Escudier B., Pluzanska A., Koralewski P., Ravaud A., Bracarda S., Szczylik C., Chevreau C., Filipek M., Melichar B., Bajetta E., Gorbunova V., Bay J.O., Bodrogi I., Jagiello-Gruszfeld A., Moore N., Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, doubleblind phase III trial. Lancet, 2007, 370, 2103-2111.
18. Essafi-Benkhadir K., Onesto C., Stebe E., Moroni C., Pag̀es G., Tristetraprolin inhibits Ras-dependent tumor vascularization by inducing vascular endothelial growth factor mRNA degradation.Mol Biol Cell, 2007, 18, 4648-4658.
19. Ferrara N., Kerbel R.S., Angiogenesis as a therapeutic target. Nature, 2005, 438, 967-974.
20. Finkenzeller G., Marme D., Weich H.A., Hug H., Plateletderived growth factor-induced transcription of the vascular endothelial growth factor gene is mediated by protein kinase C. Cancer Res, 1992, 52, 4821-4823.
21. Foekens J.A., Peters H.A., Grebenchtchikov N., Look M.P., Meijer-van Gelder M.E., Geurts-Moespot A., van der Kwast T.H., Sweep C.G., Klijn J.G., High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res, 2001, 61, 5407-5414.
22. FoxW.D., Higgins B., Maiese K.M., Drobnjak M., Cordon- Cardo C., Scher H.I., Agus D.B., Antibody to vascular endothelial growth factor slows growth of an androgenindependent xenograft model of prostate cancer. Clin Cancer Res, 2002, 8, 3226-3231.
23. Gerber H.P., Ferrara N., Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res, 2005, 65, 671-680.
24. Gille J., Swerlick R.A., Caughman S.W., Transforming growth factor alpha induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2 dependent DNA binding and transactivation. EMBO J, 1997, 16, 750-759.
25. Gridelli C., Maione P., Del Gaizo F., Colantuoni G., Guerriero C., Ferrara C., Nicolella D., Comunale D., De Vita A., Rossi A., Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist, 2007, 12, 191-200.
26. Hanahan D., Folkman J., Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 1996, 86, 353-364.
27. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 2004, 350, 2335-2342.
28. Ishigami S.I., Arii S., Furutani M., Niwano M., Harada T., Mizumoto M., Mori A., Onodera H., Imamura M., Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer, 1998, 78, 1379-1384.
29. Izumi Y., Xu L., di Tomaso E., Fukumura D., Jain R.K., Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature, 2002, 416, 279-280.
30. Jacobsen J., Rasmuson T., Grankvist K., Ljungberg B., Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol, 2000, 163, 343-347.
31. Jain R.K., Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat Rev Cancer, 2008, 8, 309-316.
32. Katsanou V., Dimitriou M., Kontoyiannis D.L., Posttranscriptional regulators in inflammation: exploring new avenues in biological therapeutics. Ernst Schering Found Symp Proc, 2006, 37-57.
33. Kerbel R.S., Tumor angiogenesis: past, present and the near future. Carcinogenesis. 2000, 21, 505-515.
34. Kindler H.L., Friberg G., Singh D.A., Locker G., Nattam S., Kozloff M., Taber D.A., Karrison T., Dachman A., Stadler W.M., Vokes E.E., Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol, 2005, 23, 8033-8040.
35. Klagsbrun M., Eichmann A., A role for axon guidance receptors and ligands in blood vessel development and tumor angiogenesis. Cytokine Growth Factor Rev, 2005, 16, 535-548.
36. Laughner E., Taghavi P., Chiles K., Mahon P.C., Semenza G.L., HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol, 2001, 21, 3995-4004.
37. Legros L., Bourcier C., Jacquel A., Mahon F.X., Cassuto J.P., Auberger P., Pag̀es G., Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia. Blood, 2004, 104, 495-501.
38. Ĺevy N.S., Chung S., Furneaux H., Ĺevy A.P., Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem, 1998, 273, 6417-6423.
39. Lopez de Silanes I., Fan J., Yang X., Zonderman A.B., Potapova O., Pizer E.S., Gorospe M., Role of the RNA-binding protein HuR in colon carcinogenesis. Oncogene, 2003, 22, 7146-7154.
40. Lu M., Amano S., Miyamoto K., Garland R., Keough K., Qin W., Adamis A.P., Insulin-induced vascular endothelial growth factor expression in retina. Invest Ophthalmol Vis Sci, 1999, 40, 3281-3286.
41. Marchetti S., Gimond C., Roux D., Gothie E., Pouysśegur J., Pag̀es G., Inducible expression of a MAP kinase phosphatase-3-GFP chimera specifically blunts fibroblast growth and ras-dependent tumor formation in nude mice. J Cell Physiol, 2004, 199, 441-450.
42. Marderosian M., Sharma A., Funk A.P., Vartanian R., Masri J., Jo O.D., Gera J.F., Tristetraprolin regulates Cyclin D1 and c-Myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling. Oncogene, 2006, 25, 6277-6290.
43. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., Schreck R.E., Abrams T.J., Ngai T.J., Lee L.B., Murray L.J., Carver J., Chan E., Moss K.G., Haznedar J.O., Sukbuntherng J., Blake R.A., Sun L., Tang C., Miller T., Shirazian S., McMahon G., Cherrington J.M., In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res, 2003, 9, 327-337.
44. Milanini J., Vinals F., Pouysśegur J., Pag̀es G., p42/p44 MAP Kinase module plays a key role in the transcriptional regulation of vascular endothelial growth factor gene in fibroblasts. J Biol Chem, 1998, 273, 18165-18172.
45. Milanini-Mongiat J., Pouysśegur J., Pag̀es G., Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription. J Biol Chem, 2002, 277, 20631-20639.
46. Miquerol L., Langille B.L., Nagy A., Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. Development, 2000, 127, 3941-3946.
47. Mylonis I., Chachami G., Samiotaki M., Panayotou G., Paraskeva E., Kalousi A., Georgatsou E., Bonanou S., Simos G., Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha. J Biol Chem, 2006, 281, 33095-33106.
48. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z., Vascular Endothelial Growth Factor (VEGF) and its receptors. FASEB J, 1999, 13, 9-22.
49. O'Farrell A.M., Abrams T.J., Yuen H.A., Ngai T.J., Louie S.G., Yee K.W., Wong L.M., Hong W., Lee L.B., Town A., Smolich B.D., Manning W.C., Murray L.J., Heinrich M.C., Cherrington J.M., SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood, 2003, 101, 3597-3605.
50. Onesto C., Hannoun-Ĺevi J.M., Chamorey E., Formento J.L., Ramaioli A., Pag̀es G., Vascular endothelial growth factor-A and Poly(A) binding proteininteracting protein 2 expression in human head and neck carcinomas: correlation and prognostic significance. Br J Cancer, 2006, 94, 1516-1523.
51. Onesto C., Berra E., Gŕepin R., Pag̀es G., Poly(A)-binding protein-interacting protein 2, a strong regulator of vascular endothelial growth factor mRNA. J Biol Chem, 2004, 279, 34217-34226.
52. Pag̀es G., Sp3-Mediated VEGF regulation is dependent on phosphorylation by extra-cellular signals regulated kinases (Erk). J Cell Physiol, 2007, 213, 454-463.
53. Pelletier F., Bermont L., Puzenat E., Blanc D., Cairey-Remonnay S., Mougin C., Laurent R., Humbert P., Aubin F., Circulating vascular endothelial growth factor in cutaneous malignant melanoma. Br J Dermatol, 2005, 152, 685-689.
54. Perrin R.M., Konopatskaya O., Qiu Y., Harper S., Bates D.O., Churchill A.J., Diabetic retinopathy is associated with a switch in splicing from anti- to proangiogenic isoforms of vascular endothelial growth factor. Diabetologia, 2005, 48, 2422-2427.
55. Pivot X., Bevacizumab in first-line treatment of metastatic breast cancer: a viewpoint by Xavier Pivot. Drugs, 2007, 67, 1800-1801.
56. Pore N., Liu S., Shu H.K., Li B., Haas-Kogan D., Stokoe D., Milanini-Mongiat J., Pag̀es G., O'Rourke D.M., Bernhard E., Maity A., Sp1 is involved in Aktmediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell, 2004, 15, 4841-4853.
57. Press M.F., Lenz H.J., EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs, 2007, 67, 2045-2075.
58. Presta L.G., Chen H., O'Connor S.J., Chisholm V., Meng Y.G., Krummen L., Winkler M., Ferrara N., Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res, 1997, 57, 4593-4599.
59. Rak J., Mitsuhashi Y., Sheehan C., Tamir A., Vioria-Petit A., Filmus J., Mansour S.J., Ahn N.G., Kerbel R.S., Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras transformed epithelial cells and fibroblasts. Cancer Res., 2000, 60, 490-498.
60. Ramaswamy B., Elias A.D., Kelbick N.T., Dodley A., Morrow M., Hauger M., Allen J., Rhoades C., Kendra K., Chen H.X., Eckhardt S.G., Shapiro C.L., Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res, 2006, 12, 3124-3129.
61. Richard D.E., Berra E., Gothie E., Roux D., Pouysśegur J., p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem, 1999, 274, 32631-32637.
62. Rini B.I., Michaelson M.D., Rosenberg J.E., Bukowski R.M., Sosman J.A., Stadler W.M., Hutson T.E., Margolin K., Harmon C.S., DePrimo S.E., Kim S.T., Chen I., George D.J., Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumabrefractory metastatic renal cell carcinoma. J Clin Oncol, 2008, 26, 3743-3748.
63. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., Lilenbaum R., Johnson D.H., Paclitaxelcarboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med, 2006, 355, 2542-2550.
64. Seo Y., Baba H., Fukuda T., Takashima M., Sugimachi K., High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer, 2000, 88, 2239-2245.
65. Shih S.C., Claffey K.P., Regulation of human vascular endothelial growth factor mRNA stability in hypoxia by heterogeneous nuclear ribonucleoprotein L. J Biol Chem, 1999, 274, 1359-1365.
66. Stoecklin G., Gross B., Ming X.F., Moroni C., A novel mechanism of tumor suppression by destabilizing AU-rich growth factor mRNA. Oncogene, 2003, 22, 3554-3561.
67. Strowski M.Z., Cramer T., Schafer G., Juttner S.,Walduck A., Schipani E., Kemmner W., Wessler S., Wunder C., Weber M., Meyer T.F., Wiedenmann B., Jons T., Naumann M., Hocker M., Helicobacter pylori stimulates host vascular endothelial growth factor-A (vegf- A) gene expression via MEK/ERK-dependent activation of Sp1 and Sp3. Faseb J, 2004, 18, 218-220.
68. Toi M., Matsumoto T., Bando H., Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol, 2001, 2, 667-673.
69. Varey A.H., Rennel E.S., Qiu Y., Bevan H.S., Perrin R.M., Raffy S., Dixon A.R., Paraskeva C., Zaccheo O., Hassan A.B., Harper S.J., Bates D.O., VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGFA isoforms has implications for therapy. Br J Cancer, 2008, 98, 1366-1379.
70. Warren R.S., Yuan H., Matli M.R., Ferrara N., Donner D.B., Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem, 1996, 271, 29483-29488.
71. Wilhelm S., Chien D.S., BAY 43-9006: preclinical data. Curr Pharm Des, 2002, 8, 2255-2257.
72. Woolard J., Wang W.Y., Bevan H.S., Qiu Y., Morbidelli L., Pritchard-Jones R.O., Cui T.G., SugionoM.,Waine E., Perrin R., Foster R., Digby-Bell J., Shields J.D., Whittles C.E., Mushens R.E., Gillatt D.A., Ziche M., Harper S.J., Bates D.O., VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res, 2004, 64, 7822-7835.
73. Yamamoto S., Konishi I., Mandai M., Kuroda H., Komatsu T., Nanbu K., Sakahara H., Mori T., Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer, 1997, 76, 1221-1227.
74. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., Steinberg S.M., Chen H.X., Rosenberg S.A., A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med, 2003, 349, 427-434.
75. Yen L., Benlimame N., Nie Z.R., Xiao D., Wang T., Al Moustafa A.E., Esumi H., Milanini J., Hynes N.E., Pag̀es G., Alaoui-Jamali M.A., Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. Mol Biol Cell, 2002, 13, 4029-4044.
76. Yuan A., Yu C.J., Shun C.T., Luh K.T., Kuo S.H., Lee Y.C., Yang P.C., Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int J Cancer, 2005, 115, 545-555.
77. Zhang Y.W., Su Y., Volpert O.V., Van de Woude G.F., Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A, 2003a, 100, 12718-12723.
78. Zhang L., Yang N., Katsaros D., Huang W., Park J.W., Fracchioli S., Vezzani C., Rigault de la Longrais, I.A., Yao W., Rubin S.C., Coukos G., The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. Cancer Res, 2003b, 63, 4225-4231.